세계의 두경부암 치료제 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 치료 유형별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2024-2030년)

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy), By Route Of Administration (Injectable, Oral), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

두경부암 치료제 시장의 성장 및 동향 :

Grand View Research의 최신 보고서에 따르면 세계의 두경부암 치료제 시장 규모는 2030년까지 44억 3,000만 달러에 달할 전망입니다.

이 시장은 2024년부터 2030년까지 CAGR 11.8%로 성장할 것으로 예측됩니다. 두경부암(HNC)의 진단과 치료에 있어서의 진보 증가는 비용 효과가 높고, 수술보다 표적이 특정되기 때문에 시장 성장을 가속할 것으로 예측되고 있습니다. 다양한 유형의 HNC 유병률 증가 및 노인 인구 증가가 시장의 주요 촉진요인입니다.

암연구소에 따르면 2021년에는 미국에서 약 5만 4,000명이 다른 유형의 HNC로 진단되어 약 1만 1,000명이 사망했다고 보고되었습니다. 대량의 알코올 섭취, 장시간의 일광 노출, 엡스타인 바 바이러스(EBV) 등의 암을 일으키는 바이러스 감염, 담배의 소비는 세계적으로 다양한 두경부암의 발생률 상승에 기여하는 주요 요인의 일부입니다.

또한 유엔에 따르면 2020년에는 전 세계에서 60세 이상의 노인이 약 7억 2,700만 명이 될 것으로 추정되고 있습니다. 또한 노인 인구는 2020년 9.3%에서 2050년 16%로 증가할 것으로 예상됩니다. 노화는 면역력을 감소시키고 다양한 유형의 HNC에 걸리기 쉽기 때문에 질병 치료에 대한 치료 수요가 증가합니다.

게다가 신규 표적약이나 집학적 치료 접근법의 개발을 위한 연구개발 활동 증가는 두경부암을 앓고 있는 환자의 생존율의 상승으로 이어질 것으로 예상됩니다. 예를 들어, Merck/Debiopharm의 Xevinapant는 두경부 편평상피암의 치료로서 현재 3상 임상시험 중입니다. 미국 FDA로부터 획기적인 치료의 지정을 받고 있습니다.

지원적인 상환 정책도 시장 성장의 원동력이 될 것으로 예상됩니다. 여러 단체가 환자와 그 간병인이 의약품을 구입할 때 자금 지원을 실시했습니다. 예를 들어, 2022년 7월 영국 콜롬비아 암은 카페시타빈, 카르보플라틴, 세툭시맙, 시스플라틴, 도세탁셀, 독소루비신, 플루오로우라실, 류코보린 칼슘을 급여 약물 목록에 포함시켰습니다. 이 목록에 포함된 약물은 승인된 적응증에 대한 상환에 적용됩니다.

두경부암 치료제 시장 보고서 하이라이트

• 면역요법이 시장을 선도하고 2023년 세계 수익 점유율의 60.07%를 차지했으며, 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예측됩니다.
• 주사제는 2023년에 시장을 선도하였고, 예측 기간 동안 CAGR은 12.0%로 성장할 것으로 예측됩니다. 주사제는 전신 요법에서 중요한 역할을 하며 악성 종양 세포와 싸우기 위한 표적 약물을 전달합니다.
• 소매 및 전문 약국은 2023년 시장 점유율 57.67%로 시장을 선도하였고 예측 기간 동안 가장 빠른 CAGR로 성장할 전망입니다.
• 아시아태평양의 두경부암 치료제 시장은 두경부암의 유병률 증가, 악성종양 치료에 대한 의식 증가, 가처분소득 증가, 의료개혁 진전으로 동 시장에서 가장 급속한 성장이 예상됩니다.

목차

제1장 조사 방법 및 범위

제2장 주요 요약

제3장 두경부암 치료제 시장의 변수, 동향 및 범위

• 두경부암 치료제 시장의 계통 전망
  • 상위 시장 전망
  • 보조 시장
• 시장 역학
  • 시장 드라이버 분석
  • 시장 성장 억제요인 분석
• 두경부암 치료제 시장 분석 도구
  • Porter's Five Forces 분석
  • 거시경제 분석
• 파이프라인 분석
  • 임상시험 중 제3상 파이프라인 의약품

제4장 두경부암 치료제 시장 : 치료 유형별 비즈니스 분석

• 두경부암 치료제 시장 : 치료 유형별 변동 분석
• 변동 분석 및 시장 점유율 : 치료 유형별(2023년, 2030년)
• 화학요법
• 면역요법
• 표적요법

제5장 두경부암 치료제 시장 : 투여 경로별 비즈니스 분석

• 두경부암 치료제 시장 : 투여 경로별 변동 분석
• 변동 분석 및 시장 점유율 : 투여 경로별(2023년, 2030년)
• 주사
• 경구

제6장 두경부암 치료제 시장 : 유통 채널별 비즈니스 분석

• 두경부암 치료제 시장 : 유통 채널별 변동 분석
• 변동 분석 및 시장 점유율 : 유통 채널별(2023년, 2030년)
• 소매 및 전문 약국
• 병원 약국
• 온라인 약국

제7장 두경부암 치료제 시장 : 지역별 추정 및 동향 분석, 치료 유형별, 투여 경로별, 유통 채널별

• 두경부암 치료제 시장 : 지역별 전망
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제8장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향 및 영향 분석
• 기업 분류
• 벤더 상황
  • 주요 기업의 시장 점유율 분석(2023년)
  • Eli Lilly and Company
  • Sanofi
  • Merck &Co., Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company(BMS)
  • AstraZeneca
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd

AJY

영문 목차

영문목차

Head And Neck Cancer Therapeutics Market Growth & Trends:

The global head and neck cancer therapeutics market size is expected to reach USD 4.43 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 11.8% from 2024 to 2030. Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market.

According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.

Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.

Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm's Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.

Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.

Head And Neck Cancer Therapeutics Market Report Highlights:

• Immunotherapy led the market and accounted for 60.07% of the global revenue share in 2023 and is expected to grow at the fastest CAGR during the forecast period.
• Injectable led the market in 2023 and is expected to grow at a CAGR of 12.0% over the forecast period. Injectable medications play an important role in systemic therapies, delivering targeted agents to combat malignancy cells.
• Retail & specialty pharmacies led the market with a market share of 57.67% in 2023 and is expected to grow at the fastest CAR during the forecast period.
• The head and neck cancer therapeutics market in Asia Pacific is anticipated to witness the fastest growth in the market owing to the increasing prevalence of head & neck cancer, growing awareness about malignancy treatment, rising disposable income, and increasing healthcare reforms.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapy Type
  • 1.2.2. Route of Administration
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Therapy Type and Route of Administration Segment Snapshot
• 2.3 Distribution Channel Segment Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 Head and Neck Cancer Therapeutics Market Variables, Trends, and Scope

• 3.1 Head and Neck Cancer Therapeutics Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
  • 3.1.2 Ancillary Market
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Analysis
    • 3.2.1.1 Increase in Prevalence of Head and Neck Cancers
    • 3.2.1.2 Rising Geriatric Population
    • 3.2.1.3 Increasing R&D and Strong Presence of Pipeline Products
    • 3.2.1.4 Supportive Reimbursement Policies & Rising Awareness About Disease
  • 3.2.2 Market Restraint Analysis
    • 3.2.2.1 Paucity of Data Related to Safety and Efficacy
    • 3.2.2.2 High Cost of Treatment
• 3.3 Head and Neck Cancer Therapeutics Market Analysis Tools
  • 3.3.1 Porter's Five Forces Analysis
  • 3.3.2 Macroeconomic Analysis
• 3.4 Pipeline Analysis
  • 3.4.1 Phase 3 Pipeline drugs under clinical trails

Chapter 4 Head and Neck Cancer Therapeutics Market: Therapy Type Business Analysis

• 4.1 Head and Neck Cancer Therapeutics Market: Therapy Type Movement Analysis
• 4.2 Therapy Type Movement Analysis & Market Share, 2023 & 2030
• 4.3 Chemotherapy
  • 4.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.4 Immunotherapy
  • 4.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5 Targeted Therapy
  • 4.5.1 Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5 Head and Neck Cancer Therapeutics Market: Route of Administration Business Analysis

• 5.1 Head and Neck Cancer Therapeutics Market: Route of Administration Movement Analysis
• 5.2 Route of Administration Movement Analysis & Market Share, 2023 & 2030
• 5.3 Injectable
  • 5.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.4 Oral
  • 5.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6 Head and Neck Cancer Therapeutics Market: Distribution Channel Business Analysis

• 6.1 Head and Neck Cancer Therapeutics Market: Distribution Channel Movement Analysis
• 6.2 Distribution Channel Movement Analysis & Market Share, 2023 & 2030
• 6.3 Retail & Specialty Pharmacies
  • 6.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.4 Hospital Pharmacies
  • 6.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5 Online Pharmacies
  • 6.5.1 Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7 Head and Neck Cancer Therapeutics Market: Regional Estimates and Trend Analysis, by Therapy Type, by Route of Administration, by Distribution Channel

• 7.1 Head and Neck Cancer Therapeutics Market: Regional Outlook
• 7.2 North America
  • 7.2.1 North America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2 U.S.
    • 7.2.2.1 Key Country Dynamics
    • 7.2.2.2 U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2.3 Target Disease: Cancer Incidence
    • 7.2.2.4 Market and Competitive Scenario
    • 7.2.2.5 Regulatory Framework
    • 7.2.2.6 Reimbursement Scenario
  • 7.2.3 Canada
    • 7.2.3.1 Key Country Dynamics
    • 7.2.3.2 Canada Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3.3 Target Disease: Cancer Incidence
    • 7.2.3.4 Market and Competitive Scenario
    • 7.2.3.5 Regulatory Framework
    • 7.2.3.6 Reimbursement Scenario
• 7.3 Europe
  • 7.3.1 Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2 UK
    • 7.3.2.1 Key Country Dynamics
    • 7.3.2.2 UK Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2.3 Target Disease Prevalence
    • 7.3.2.4 Market and Competitive Scenario
    • 7.3.2.5 Regulatory Framework
    • 7.3.2.6 Reimbursement Scenario
  • 7.3.3 Germany
    • 7.3.3.1 Key Country Dynamics
    • 7.3.3.2 Germany Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3.3 Target Disease Prevalence
    • 7.3.3.4 Market and Competitive Scenario
    • 7.3.3.5 Regulatory Framework
    • 7.3.3.6 Reimbursement Scenario
  • 7.3.4 France
    • 7.3.4.1 Key Country Dynamics
    • 7.3.4.2 France Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4.3 Target Disease Prevalence
    • 7.3.4.4 Market and Competitive Scenario
    • 7.3.4.5 Regulatory Framework
    • 7.3.4.6 Reimbursement Scenario
  • 7.3.5 Spain
    • 7.3.5.1 Key Country Dynamics
    • 7.3.5.2 Spain Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5.3 Target Disease Prevalence
    • 7.3.5.4 Market and Competitive Scenario
    • 7.3.5.5 Regulatory Framework
    • 7.3.5.6 Reimbursement Scenario
  • 7.3.6 Italy
    • 7.3.6.1 Key Country Dynamics
    • 7.3.6.2 Italy Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6.3 Target Disease Prevalence
    • 7.3.6.4 Market and Competitive Scenario
    • 7.3.6.5 Regulatory Framework
    • 7.3.6.6 Reimbursement Scenario
  • 7.3.7 Denmark
    • 7.3.7.1 Key Country Dynamics
    • 7.3.7.2 Denmark Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7.3 Target Disease Prevalence
    • 7.3.7.4 Market and Competitive Scenario
    • 7.3.7.5 Regulatory Framework
    • 7.3.7.6 Reimbursement Scenario
  • 7.3.8 Sweden
    • 7.3.8.1 Key Country Dynamics
    • 7.3.8.2 Sweden Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8.3 Target Disease Prevalence
    • 7.3.8.4 Market and Competitive Scenario
    • 7.3.8.5 Regulatory Framework
    • 7.3.8.6 Reimbursement Scenario
  • 7.3.9 Norway
    • 7.3.9.1 Key Country Dynamics
    • 7.3.9.2 Norway Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9.3 Target Disease Prevalence
    • 7.3.9.4 Market and Competitive Scenario
    • 7.3.9.5 Regulatory Framework
    • 7.3.9.6 Reimbursement Scenario
  • 7.3.10 Rest of Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4 Asia Pacific
  • 7.4.1 Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2 Japan
    • 7.4.2.1 Key Country Dynamics
    • 7.4.2.2 Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2.3 Target Disease Prevalence
    • 7.4.2.4 Market and Competitive Scenario
    • 7.4.2.5 Regulatory Framework
    • 7.4.2.6 Reimbursement Scenario
  • 7.4.3 China
    • 7.4.3.1 Key Country Dynamics
    • 7.4.3.2 China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3.3 Target Disease Prevalence
    • 7.4.3.4 Market and Competitive Scenario
    • 7.4.3.5 Regulatory Framework
    • 7.4.3.6 Reimbursement Scenario
  • 7.4.4 India
    • 7.4.4.1 Key Country Dynamics
    • 7.4.4.2 India Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4.3 Target Disease Prevalence
    • 7.4.4.4 Market and Competitive Scenario
    • 7.4.4.5 Regulatory Framework
    • 7.4.4.6 Reimbursement Scenario
  • 7.4.5 Australia
    • 7.4.5.1 Key Country Dynamics
    • 7.4.5.2 Australia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5.3 Target Disease Prevalence
    • 7.4.5.4 Market and Competitive Scenario
    • 7.4.5.5 Regulatory Framework
    • 7.4.5.6 Reimbursement Scenario
  • 7.4.6 Thailand
    • 7.4.6.1 Key Country Dynamics
    • 7.4.6.2 Thailand Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6.3 Target Disease Prevalence
    • 7.4.6.4 Market and Competitive Scenario
    • 7.4.6.5 Regulatory Framework
    • 7.4.6.6 Reimbursement Scenario
  • 7.4.7 South Korea
    • 7.4.7.1 Key Country Dynamics
    • 7.4.7.2 South Korea Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7.3 Target Disease Prevalence
    • 7.4.7.4 Market and Competitive Scenario
    • 7.4.7.5 Regulatory Framework
    • 7.4.7.6 Reimbursement Scenario
  • 7.4.8 Rest of Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5 Latin America
  • 7.5.1 Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2 Brazil
    • 7.5.2.1 Key Country Dynamics
    • 7.5.2.2 Brazil Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2.3 Target Disease Prevalence
    • 7.5.2.4 Competitive Scenario
    • 7.5.2.5 Regulatory Framework
    • 7.5.2.6 Reimbursement Scenario
  • 7.5.3 Mexico
    • 7.5.3.1 Key Country Dynamics
    • 7.5.3.2 Mexico Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3.3 Target Disease: Cancer Incidence
    • 7.5.3.4 Market and Competitive Scenario
    • 7.5.3.5 Regulatory Framework
    • 7.5.3.6 Reimbursement Scenario
  • 7.5.4 Argentina
    • 7.5.4.1 Key Country Dynamics
    • 7.5.4.2 Argentina Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4.3 Target Disease Prevalence
    • 7.5.4.4 Competitive Scenario
    • 7.5.4.5 Regulatory Framework
    • 7.5.4.6 Reimbursement Scenario
  • 7.5.5 Rest of Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6 Middle East and Africa
  • 7.6.1 MEA Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2 South Africa
    • 7.6.2.1 Key Country Dynamics
    • 7.6.2.2 South Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2.3 Target Disease Prevalence
    • 7.6.2.4 Competitive Scenario
    • 7.6.2.5 Regulatory Framework
    • 7.6.2.6 Reimbursement Scenario
  • 7.6.3 Saudi Arabia
    • 7.6.3.1 Key Country Dynamics
    • 7.6.3.2 Saudi Arabia Head and Neck Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3.3 Target Disease Prevalence
    • 7.6.3.4 Competitive Scenario
    • 7.6.3.5 Regulatory Framework
    • 7.6.3.6 Reimbursement Scenario
  • 7.6.4 UAE
    • 7.6.4.1 Key Country Dynamics
    • 7.6.4.2 UAE Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4.3 Target Disease Prevalence
    • 7.6.4.4 Competitive Scenario
    • 7.6.4.5 Regulatory Framework
    • 7.6.4.6 Reimbursement Scenario
  • 7.6.5 Kuwait
    • 7.6.5.1 Key Country Dynamics
    • 7.6.5.2 Kuwait Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5.3 Target Disease Prevalence
    • 7.6.5.4 Competitive Scenario
    • 7.6.5.5 Regulatory Framework
    • 7.6.5.6 Reimbursement Scenario
  • 7.6.6 Rest of MEA Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Competitive Landscape

• 8.1 Recent Developments & Impact Analysis, By Key Market Participants
• 8.2 Company Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Eli Lilly and Company
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Sanofi
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.6. Merck & Co., Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.7. Cumberland Pharmaceuticals, Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.8. Bristol-Myers Squibb Company (BMS)
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.9. AstraZeneca
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.10. Takeda Pharmaceutical Company Limited
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.11. Teva Pharmaceutical Industries Ltd.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.12. F. Hoffmann-La Roche Ltd
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives

관련자료